HIV-1 gp120 influences the expression of microRNAs in human monocyte-derived dendritic cells via STAT3 activation

Andrea Masotti1†, Gloria Donninelli2†, Letizia Da Sacco1, Barbara Varano2, Manuela Del Cornò2* and Sandra Gessani2*

Abstract

Background: MicroRNAs (miRs) are an abundant class of small non-coding RNAs (~22 nt) that reprogram gene expression by targeting mRNA degradation and translational disruption. An emerging concept implicates miR coupling with transcription factors in myeloid cell development and function, thus contributing to host defense and inflammation. The important role that these molecules play in the pathogenesis of HIV-1 is only now emerging.

Results: We provide evidence that exposure of monocyte-derived dendritic cells (MDDCs) to recombinant HIV-1 R5 gp120, but not to CCR5 natural ligand CCL4, influences the expression of a panel of miRs (i.e., miR-21, miR-155 and miR-181b) regulated by STAT3 and potentially targeting genes belonging to the STAT3 signaling pathway. The blockage of gp120-induced STAT3 activation impairs gp120 capacity to modulate the expression level of above mentioned miRs. Predictive analysis of miR putative targets emphasizes that these miRs share common target genes. Furthermore, gene ontology and pathway enrichment analysis outline that these genes mainly belong to biological processes related to regulation of transcription, in a complex network of interactions involving pathways relevant to HIV-DC interaction.

Conclusions: Overall, these results point to gp120-triggered modulation of miR expression via STAT3 activation as a novel molecular mechanism exploited by HIV-1 to affect DC biology and thus modulate the immune response through complex regulatory loops involving, at the same time, miRs and transcription factors.

Keywords: microRNA, HIV-1, Dendritic cell, STAT3, gp120

Background

MicroRNAs (miRs) are an abundant class of small non-coding RNAs (~22 nt) that function to control gene expression and restrict viral replication in host cells [1, 2]. Dysregulation of miRs expression is associated with numerous disease states. The human genome encodes hundreds of miRs with the potential to regulate up to 92 % of genes, mostly through inhibition of translation and/or promotion of mRNA degradation. Growing evidence indicates that miRs and transcription factors can jointly regulate target gene expression in the form of feed-forward or feedback loops [3]. These regulatory loops serve as important motifs in functional networks and play critical roles in multiple biological processes, either in healthy states or diseases. miR-mediated gene silencing has been shown to be a key event in viral pathogenesis [4–6]. Several cellular miRs show substantial changes in expression upon HIV-1 infection [6, 7], and contributes to viral latency in primary CD4+ T lymphocytes [8]. HIV-1 infectivity has been reported to be influenced by cellular miRs [9]. Multiple cellular miRs can modulate both viral infectivity and replication by targeting directly the viral genome or decreasing the expression of host proteins required for virus replication [1]. More recently, changes in miRs expression profile of CD4+ T lymphocytes after exposure to HIV-1 allowed to discriminate among different stages of HIV infection [10].

* Correspondence: manuela.delcorno@iss.it; sandragessani@iss.it
†Equal contributors
2Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
Full list of author information is available at the end of the article

© 2015 Masotti et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Dendritic cells (DCs) are professional antigen presenting cells playing a critical role in the orchestration and fine-tuning of the immune response [11]. At the mucosal sites, they are primary targets of HIV-1 infection, co-opted by the virus to facilitate its transfer to T lymphocyte and body dissemination [12]. However, how HIV-1 manipulates DC biology to use these cells to its own advantage without marked cytopathic effects is still unclear. In these cells, the interaction of the envelope protein gp120 with surface receptors triggers early signaling events even in the absence of productive infection and may profoundly influence cellular behavior and secretory profile [13]. In this respect, we have recently reported that DC exposure to HIV-1 R5 gp120 resulted in production of IL-6 via MAPK/NF-kB pathways which, in turn, activated STAT3 by an autocrine loop [14]. This modulation is dependent on C-C chemokine receptor 5 (CCR5), the principal coreceptor of HIV-1 entry in DC, and it is specific for gp120, since the C-C chemokine ligand 4 (CCL4), the most specific natural ligand for CCR5, did not induce IL-6 production and STAT3 activation in these cells [14].

Interestingly, a growing body of evidence demonstrates that miRs are closely associated with the STAT3 signaling pathway supporting the existence of regulatory feedback loops between miRs and several components of the STAT3 pathway in different cancer contexts [15].

In this study, we performed a bioinformatics analysis to identify a panel of miRs that present one or more STAT3 binding sites in their promoter region. Moreover, we selected miR targeting genes belonging to STAT3 signaling pathway and determined whether the addition of gp120 to monocyte-derived DCs (MDDCs) would alter their expression levels. We found that gp120-triggered STAT3 activation directly influenced the expression of miR-21, miR-181b and miR-155. Bioinformatics analysis of miR putative targets unraveled that these genes are primarily regulated by STAT3 and targeting genes annotated in the miRWalk database whose targets belong to STAT3 signaling pathway. This analysis led to a restricted list of 14 miRs potentially regulated by STAT3 and targeting genes annotated in the STAT3 signaling pathway (Biocarta) that is shown in Table 2. Detailed information on this analysis is provided in additional file 2. Interestingly, some of the miRs reported in Table 2 (i.e., miR-21, miR-125b, miR-135b, miR-181b and miR-155) were already predicted to be regulated by STAT3 and also experimentally validated [16, 18–21].

**HIV-1 gp120-induced activation of STAT3 modulates miR expression profiles in MDDCs**

On the basis of the bioinformatics analyses illustrated above, we first experimentally validated a panel of miRs including miR-21, miR-125b, miR-135b and miR-181b in gp120-treated MDDCs by real-time quantitative PCR (qPCR). As shown in Fig. 1, miR-21 (A) and miR-181b (B) were down- and up-regulated, respectively, in cells treated with R5 gp120 at 18 h. Conversely, no significant difference was observed at 6 h. Likewise, gp120 treatment did not result in any significant modulation of miR-125b, whereas miR-135b did not amplify (data not shown). Although miR modulation was quite modest, it showed reproducibility among all donors tested (n = 12) and results were statistically significant with respect to untreated controls. Then, to better define the role of STAT3 in the gp120-induced modulation of miR-21 and miR-181b, we assessed the expression profile of these miRs in the presence of Statistic, a non-peptidic small molecule inhibiting STAT3 activation and dimerization [22]. Although the addition of Statistic did not per se modulate the baseline expression levels of these miRs, it completely abolished the gp120-induced down-modulation of miR-21 (C) as well as the up-modulation of miR-181b (D), thus confirming a role for STAT3 in the regulation of these miRs in MDDCs.

HIV-1 gp120 and LPS have been reported to induce, at some extent, overlapping effects in a variety of cell types, as both molecules promote cytokine/chemokine secretion and modulate cell activation state. Furthermore,
**Table 1** Analysis of the promoter regions of putative STAT3 regulated miRs

| miR           | MA0144.1 | M00225 | M00497 | Total |
|---------------|----------|--------|--------|-------|
| hsa-mir-3124  | 8        | 12     | 5      | 25    |
| hsa-mir-92b   | 6        | 12     | 4      | 22    |
| hsa-mir-1205  | 11       | 4      | 6      | 21    |
| hsa-mir-1206  | 7        | 12     | 1      | 20    |
| hsa-mir-1256  | 9        | 8      | 2      | 19    |
| hsa-mir-629   | 4        | 11     | 4      | 19    |
| hsa-mir-146a  | 2        | 5      | 12     | 19    |
| hsa-mir-3125  | 10       | 7      | 1      | 18    |
| hsa-mir-1255a | 10       | 6      | 2      | 18    |
| hsa-mir-3142  | 9        | 7      | 2      | 18    |
| hsa-mir-125b-2| 8        | 8      | 2      | 18    |
| hsa-mir-155   | 8        | 5      | 4      | 17    |
| hsa-mir-30e   | 8        | 3      | 5      | 16    |
| hsa-mir-64S   | 11       | 2      | 3      | 16    |
| hsa-mir-181b-1| 6        | 3      | 7      | 16    |
| hsa-mir-1537  | 9        | 4      | 2      | 15    |
| hsa-mir-3197  | 6        | 7      | 2      | 15    |
| hsa-mir-21    | 7        | 4      | 4      | 15    |
| hsa-mir-30c-1 | 12       | 1      | 2      | 15    |
| hsa-mir-1825  | 12       | 0      | 2      | 14    |
| hsa-mir-29a   | 8        | 2      | 3      | 13    |
| hsa-mir-135b  | 7        | 2      | 4      | 13    |
| hsa-mir-1207  | 7        | 2      | 3      | 12    |
| hsa-mir-619   | 6        | 2      | 4      | 12    |
| hsa-mir-548h-1| 4        | 1      | 7      | 12    |
| hsa-mir-646   | 5        | 4      | 3      | 12    |
| hsa-let-7b    | 8        | 3      | 1      | 12    |
| hsa-mir-125b-1| 3        | 4      | 5      | 12    |
| hsa-mir-181a-2| 10       | 1      | 1      | 12    |
| hsa-mir-20b-1 | 5        | 2      | 3      | 10    |
| hsa-mir-3145  | 3        | 5      | 1      | 9     |
| hsa-mir-612   | 5        | 4      | 0      | 9     |
| hsa-mir-3174  | 4        | 3      | 2      | 9     |
| hsa-mir-630   | 2        | 4      | 3      | 9     |
| hsa-mir-451   | 8        | 1      | 0      | 9     |
| hsa-mir-20c   | 6        | 1      | 1      | 8     |
| hsa-mir-202   | 5        | 1      | 1      | 7     |
| hsa-mir-148b  | 2        | 2      | 3      | 7     |
| hsa-mir-181b-2| 4        | 3      | 0      | 7     |
| hsa-let-7a-3  | 5        | 1      | 0      | 6     |
| hsa-mir-548c  | 0        | 0      | 2      | 2     |

The number of STAT3 binding site for each sequence motif obtained by LASAGNA search is reported for each selected miR.
MDDCs activated by LPS show a typical miR expression profile that includes a remarkable up-modulation of miR-155 and to a lesser extent, of miR-146 [23–26]. Of note, both miRs have been reported to play an important role in the modulation of the immune response [23, 27]. As shown in Fig. 2, while LPS markedly up-modulated miR-155 and miR-146 expression, at early time points (6 h), gp120 exhibited a significant inhibitory effect (1.4 fold decrease) on miR-155 that disappeared at later time points (18 h), while miR-146 was not affected.

In keeping with our previous observation that CCL4 does not affect the STAT3/IL-6 axis [14], this chemokine, known as the most specific natural ligand engaging CCR5, did not alter the expression of miR-21, miR-155 and miR-181b expression, as well as that of miR-146 (Table 3).

### Gene Ontology of miR-21, miR-155 and miR-181b predicted targets

On the basis of the results on the experimental validation of gp120-modulated miRs in MDDCs, we integrated the initial target prediction analysis (Table 2) by using our previously published procedure [28] that exploits the predictions of three different algorithms (TargetScan, MiRanda and Pita; Additional file 3). By this *in-house* R bioconductor script we obtained the combined list of unique predictions for miR-21, miR-155 and miR-181b. The complete list of target genes for each of these three gp120-modulated miRs is reported in Additional file 4. We found that miR-21, miR-155 and miR-181b targeted 1119, 1468 and 2617 genes, respectively. To identify the genes targeted by more than one miR, we

| miRNA name | Targeted genes in STAT3 signaling pathway |
|------------|------------------------------------------|
| hsa-mir-21 | MAPK3, FRAP1, STAT3                      |
| hsa-mir-155| STAT3, MAPK3, JAK2, JAK1, FRAP1          |
| hsa-let-7b | STAT3, MAPK3, JAK2                       |
| hsa-let-7a-3| STAT3, MAPK3, JAK2                      |
| hsa-mir-146a| STAT3, MAPK3                             |
| hsa-mir-125b-2| MAPK3, FRAP1, STAT3                   |
| hsa-mir-125b-1| MAPK3, FRAP1, STAT3                   |
| hsa-mir-29a | FRAP1, MAPK3                             |
| hsa-mir-135b| STAT3                                   |
| hsa-mir-451 | JAK2, FRAP1                              |
| hsa-mir-30c-1| JAK2                                    |
| hsa-mir-181a-2| MAPK3                                   |
| hsa-mir-181b-2| STAT3                                   |
| hsa-mir-181b-1| STAT3                                   |

The table shows the genes present in the STAT3 signaling pathway (Biocarta) that are validated targets of a selection of STAT3 regulated miR.

---

**Table 2** List of genes in the STAT3 signaling pathway targeted by STAT3 regulated miR

| miRNA name | Targeted genes in STAT3 signaling pathway |
|------------|------------------------------------------|
| hsa-mir-21 | MAPK3, FRAP1, STAT3                      |
| hsa-mir-155| STAT3, MAPK3, JAK2, JAK1, FRAP1          |
| hsa-let-7b | STAT3, MAPK3, JAK2                       |
| hsa-let-7a-3| STAT3, MAPK3, JAK2                      |
| hsa-mir-146a| STAT3, MAPK3                             |
| hsa-mir-125b-2| MAPK3, FRAP1, STAT3                   |
| hsa-mir-125b-1| MAPK3, FRAP1, STAT3                   |
| hsa-mir-29a | FRAP1, MAPK3                             |
| hsa-mir-135b| STAT3                                   |
| hsa-mir-451 | JAK2, FRAP1                              |
| hsa-mir-30c-1| JAK2                                    |
| hsa-mir-181a-2| MAPK3                                   |
| hsa-mir-181b-2| STAT3                                   |
| hsa-mir-181b-1| STAT3                                   |

The table shows the genes present in the STAT3 signaling pathway (Biocarta) that are validated targets of a selection of STAT3 regulated miR.

---

![Fig. 1](https://example.com/fact1.png) Real-time qPCR of HIV gp120 modulated miRs. Cells were treated with gp120 for 6–18 h or left untreated in the presence or in the absence of Static (10 μM, 1 h of pretreatment) and total RNA was extracted, reverse transcribed and subjected to Real-time qPCR. Relative fold of change of expression of miR-21 a-c, miR-181b (B-D), in gp120 stimulated MDDCs against untreated controls were calculated using the comparative \( \Delta \Delta CT \) method. PCR were run in triplicate and the mean of 12 (A-B) or 5 c-d independent experiments ± SE is shown. p values were calculated by ANOVA and statistical significance is indicated vs untreated control.

---

---

---

---

![Fig. 1](https://example.com/fact1.png) Real-time qPCR of HIV gp120 modulated miRs. Cells were treated with gp120 for 6–18 h or left untreated in the presence or in the absence of Static (10 μM, 1 h of pretreatment) and total RNA was extracted, reverse transcribed and subjected to Real-time qPCR. Relative fold of change of expression of miR-21 a-c, miR-181b (B-D), in gp120 stimulated MDDCs against untreated controls were calculated using the comparative \( \Delta \Delta CT \) method. PCR were run in triplicate and the mean of 12 (A-B) or 5 c-d independent experiments ± SE is shown. p values were calculated by ANOVA and statistical significance is indicated vs untreated control.
calculated the intersections among the three lists and represented them using Venn diagrams (Fig. 3). Interestingly, 79 genes were targeted by all miRs (Additional file 5). Information concerning the putative binding sites are provided in Additional file 6.

MiRs can regulate many target genes and modulate multiple pathways at the same time. To determine the biological processes and signaling pathways implicated in gp120-induced effects in MDDCs, the predicted targets of the newly identified gp120 deregulated miRs were separately subjected to gene ontology and KEGG pathway enrichment analysis, and annotated by means of DAVID bioinformatics tool [29]. Remarkably, the most significant ($p < 0.05$) categories of biological processes identified for miR-155 and miR-181b were transcription, regulation of transcription, regulation of RNA metabolic process, DNA-dependent regulation of transcription (Table 4). No statistically significant biological processes resulted for miR-21 targets, most probably due to the highly stringent selection criteria of the algorithm used (see additional file 3). By taking the combined list of unique predictions for miR-21, miR-155 and miR-181b, the bioinformatics analysis outlined the term ‘regulation of transcription’ as the biological process with the highest number of annotated targets (772 genes) (Table 4). As expected, many transcripts annotated in the JAK/STAT signaling pathway, including STAT members (STAT1 and STAT3), STAT regulatory factors (PIAS3 and SOCS), MAPK family members such as MAPK1 (ERK2), MAP2K1 (MEK1), MAP2K4 (MEK4), MAP3K1 (MEKK1), apoptosis

Table 3 Effects of CCL4 on miR-21, miR-146, miR-155 and miR-181b

|            | Control | CCL4 (6 h) | CCL4 (18 h) | p-value |
|------------|---------|------------|-------------|---------|
| miR-21     | 1       | 0.80 ± 0.31| 0.80 ± 0.36 | 0.642   |
| miR-146    | 1       | 1.10 ± 0.29| 1.38 ± 0.23 | 0.347   |
| miR-155    | 1       | 1.15 ± 0.69| 1.11 ± 0.06 | 0.932   |
| miR-181b   | 1       | 1.31 ± 0.38| 1.51 ± 0.21 | 0.277   |

Fold changes and standard errors of miR-21, miR-146, miR-155 and miR-181b expressed in DCs after CCL4 treatment (6 and 18 h). $p$ values were calculated by ANOVA and statistical significance is indicated vs untreated control ($n = 5$)
mediators as well as cytokines and cytokine receptors (e.g., IL12A, IFNγ, CCR5, IL-1β) were found in this biological process. Furthermore, many of these genes belonged to more than one pathway, and were targeted by more than one miRs. Fig. 4 shows the network of interactions, which may be deregulated upon exposure of MDDCs to gp120 as a consequence of the altered expression of target genes, resulting from deregulation of miR-21, miR-155 and miR-181b. This network included cell growth, proliferation, fate determination, and development, immunity, pro-inflammatory effects and apoptosis pathways. As shown in Fig. 4, bioinformatics prediction outlined the presence of a huge number of potential targets for the three miRs, whose functional validation (i.e., protein expression) in our experimental model would require demanding and expensive analysis. Thus, to overcome these issues, we refined data by selecting a panel of genes targeted by one or more gp120 deregulated miR belonging to the signaling cascade previously reported to be altered in gp120-exposed MDDCs [14, 30, 31]. Among various targets, we analyzed the expression level of genes belonging to the JAK/STAT signaling pathway (i.e., STAT1, STAT2, STAT3, JAK2, PIAS3, SOCS1, SOCS3), MAPK/NF-κB signaling pathway (i.e., p38, ERK, JNK, p50, p65, IkBα, IKKβ), and apoptosis (AKT, Bcl2, BCLxL, PKR), by western blotting analysis, in gp120-exposed MDDCs. As shown in Fig. 5, the results of protein expression analysis already reported in our previous study (STAT1, STAT2, STAT3, PIAS3, SOCS3, p38, p65, IkBα) or de novo carried out on the basis of bioinformatics analysis (ERK, JNK, p50, IKKβ, JAK2, SOCS1, AKT, Bcl2, BCLxL, PKR) clearly indicate that among the putative targets analyzed, only PIAS3 and STAT1 protein expression levels are modulated, suggesting the involvement of gp120-deregulated miRs.

### Table 4 Gene Ontology analysis for STAT3-deregulated miRNA (combined and individual predictions)

| Gene Ontology ID | Gene Ontology Term | No. of genes | % | p-value | Corrected p-value (FDR) |
|-----------------|---------------------|--------------|---|---------|------------------------|
| GO:0006350      | transcription       | 246          | 16.8 | 1.06E-11 | 1.93E-08               |
| GO:0045449      | regulation of transcription | 288 | 19.7 | 6.23E-11 | 1.13E-07               |
| GO:0051252      | regulation of RNA metabolic process | 201 | 13.8 | 1.30E-07 | 2.35E-04               |
| GO:0006355      | regulation of transcription, DNA-dependent | 197 | 13.5 | 1.57E-07 | 2.85E-04               |
| GO:0045449      | regulation of transcription       | 488          | 18.7 | 7.49E-13 | 1.40E-09               |
| GO:0006350      | transcription       | 406          | 15.6 | 2.00E-12 | 3.75E-09               |
| GO:0051252      | regulation of RNA metabolic process | 345 | 13.2 | 1.05E-09 | 1.97E-06               |
| GO:0006355      | regulation of transcription, DNA-dependent | 338 | 13.0 | 1.32E-09 | 2.47E-06               |
| GO:0006350      | transcription       | 647          | 15.3 | 1.13E-19 | 2.15E-16               |
| GO:0045449      | regulation of transcription       | 772          | 18.2 | 4.94E-19 | 9.40E-16               |
| GO:0051252      | regulation of RNA metabolic process | 539 | 12.7 | 9.54E-13 | 1.82E-09               |
| GO:0006355      | regulation of transcription, DNA-dependent | 527 | 12.4 | 1.92E-12 | 3.66E-09               |
| GO:0016481      | negative regulation of transcription | 154 | 3.6 | 1.88E-07 | 3.57E-04               |
| GO:0010629      | negative regulation of gene expression | 166 | 3.9 | 2.28E-07 | 4.34E-04               |
| GO:0045934      | negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 163 | 3.8 | 3.00E-06 | 5.72E-3                |
| GO:0051172      | negative regulation of nitrogen compound metabolic process | 164 | 3.9 | 4.54E-06 | 8.64E-3                |
| GO:0031327      | negative regulation of cellular biosynthetic process | 175 | 4.1 | 5.03E-06 | 9.57E-3                |
| GO:0010558      | negative regulation of macromolecule biosynthetic process | 171 | 4.0 | 5.71E-06 | 1.09E-2                |
| GO:0008940      | negative regulation of biosynthetic process | 176 | 4.2 | 1.29E-05 | 2.45E-2                |
| GO:0000122      | negative regulation of transcription from RNA polymerase II promoter | 92 | 2.2 | 1.81E-05 | 3.45E-2                |
| GO:0007167      | enzyme linked receptor protein signaling pathway | 113 | 2.7 | 1.97E-05 | 3.75E-2                |
| GO:0006357      | regulation of transcription from RNA polymerase II promoter | 215 | 5.1 | 2.18E-05 | 4.16E-2                |

The table shows the Gene Ontology terms obtained after the bioinformatics analysis on the genes targeted by STAT3-regulated miRs, taken individually or in combination.
Discussion

miRs play important roles in many biological processes, including cellular defense against viral infection [32]. Increasing evidence has emerged that host miRs serve in animal cells to restrict viral infections. In turn, many viruses evolved strategies to counteract miRs action and may encode their own miRs [33]. In HIV-1 infection, many mechanisms underlying the capacity of the virus to induce immune destruction have been elucidated. However, the important role that miRs play in HIV-1 pathogenesis is only now emerging [9].

Studies carried out in PBMC highlighted the importance of the RNA interference machinery in HIV infection, in regulating viral replication [34] and latency [35, 36] as well as in defining different stages of disease [37]. Likewise, in monocytes/macrophages the differential expression of some miRs has been associated with susceptibility to infection [38]. Conversely, few studies have so far addressed the question of whether HIV-1 products may play a role in miRs modulation in the absence of productive infection. In this respect, Orecchini and co-workers reported a direct involvement of Tat, ectopically expressed, in the up-modulation of miR-222 [39]. Likewise, miR expression analysis carried out by Bignami and colleagues in healthy CD4+ T cells exposed to gp120 in vitro, outlined that miRs profile could be not only the result of a productive infection but also of exposure to HIV products that leave a signature in immune cells [37].

In keeping with these observations, and based on the identification of STAT3 binding motifs in the promoter region of a panel of selected miRs, we experimentally validated that MDDCs treated with gp120, show a down-regulation of miR-21 and miR-155 expression, whereas miR-181b is up-regulated at late time points. Interestingly, CCR5 engagement by one of its most specific ligand (i.e., CCL4) does not induce any change in the expression of these miRs, adding further evidence that the interaction of HIV-1 gp120 with CCR5 evokes...
complex and distinct signaling responses, differing from those activated by the coreceptors’ chemokine ligands [14, 40–46]. A growing body of evidence demonstrates that STAT3 signaling pathway is closely associated with the transcriptional regulation of some miRs including miR-21 and miR-181b [19, 47] as well as miR-155 [16, 18]. In keeping with these observations, we showed a striking direct relationship between STAT3 activation and expression of miR-21 and miR-181b since the gp120-induced deregulation of both miRs is completely reverted in the presence of Stattic. The time-course observed for the gp120-induced miR modulation support the hypothesis that late STAT3 activation via IL-6 production is responsible for this event as at earlier time points (6 h) we did not observe any changes in miRs expression. Several studies independently support the hypothesis of regulatory circuits between miR and STAT3 pathway in different cancer contexts linked to inflammation as a key component favoring tumorigenesis [15]. Of note, the miR we found concomitantly deregulated in DC upon exposure to gp120 have been previously reported to belong to a regulatory loop contributing to STAT3-mediated cancer development [15].

To the best of our knowledge, this is the first demonstration of HIV-induced miR modulation in human MDDCs. miRs are important regulators of DC differentiation and activation [27] and increased expression of miR-155 and miR-21 in DCs represents a general features associated with cell activation [24, 48]. Our finding that miR-21 and miR-155 are downregulated by gp120 together with our previous report that gp120 induces a tolerogenic-like DC phenotype [49] suggests that these HIV-modulated miRs could play a role in viral-induced DC dysfunction. In this regards, independent studies correlated miR-155 expression with HIV infectivity and spreading. In particular, Martinez-Nunez and colleagues demonstrated that increased expression of miR-155 correlates with reduced levels of DC-SIGN expression thus limiting gp120 binding to DCs [50]. Likewise, Napuri and co-workers highlighted a synergy between HIV-1 and cocaine to lower miR-155 and miR-20a in MDDCs that modulates DC-SIGN expression, DC maturation, and HIV infectivity [51]. Finally, silencing of miR-155 in murine DCs is associated with reduced production of IL-12 [52].

Moreover, gp120-deregulated miRs in MDDCs have been found to be concomitantly regulated in different experimental settings [53, 54], and reported to regulate important biological processes relevant to DC-HIV interaction, including NF-κB signaling pathway [19, 55, 56], DC maturation [23, 24, 48, 50], inflammation [56–58] and HIV replication [53]. By using a bioinformatics pipeline intersecting the predictions of three different algorithms [28], we identified ‘regulation of transcription’ as one of the most significantly enriched biological process for these miRs. Interestingly, among the overall list of miR targets, we found many genes related to the JAK/STAT signaling pathway, STAT regulatory factors, NF-κB/MAPK family
members among others (Fig. 4). Several potential targets have been experimentally validated by assessing protein expression in MDDCs exposed to gp120. However, only two genes, that we previously reported to be regulated by gp120, i.e. STAT1 and PIAS3 were found to be modulated at the protein level. Although the observation that STAT3 activation is maintained despite the persistent PIAS3 up-regulation may at first glance appear contradictory, previous studies reported that STAT3 activation and high levels of inhibitory molecules co-exist up to several hours following stimulation [59]. Overall, this suggests that despite PIAS3 overexpression, its inhibitory function on STAT3 activation might be altered in the presence of gp120 thus contributing to chronic immune activation. Furthermore, it is also worth to be considered that although STAT3 protein levels are not modulated by gp120, the levels of STAT1 are increased at late time points. In this regard, it has been reported that STAT1 and STAT3 balanced expression or phosphorylation levels may somehow regulate the extent of inflammation [60].

**Conclusions**

The new data provided by the present study add further complexity to the model we previously postulated to describe the interaction between DCs and HIV-1 in the absence of productive infection. As shown in Fig. 6, gp120 triggers a cascade of signaling events initiated by early activation of STAT3 leading to IL-6 production. Subsequently, IL-6 determines a second round of STAT3 activation responsible for miR regulation. Although it remains to be demonstrated that miR deregulation directly impact the function of molecular components belonging to STAT3 signaling, we exclude that these miRs directly regulate STAT3 expression as identical levels of protein are found independently of gp120 exposure of DC. Conversely, our data suggests that miRs could indirectly act on key regulators of STAT3/IL-6 axis ultimately contributing to the chronic immune activation observed in AIDS.

Overall, this study provides new evidence for the molecular mechanisms and signaling pathways triggered by HIV-1 in DCs, emphasizing the role of network interactions rather than individual connections among signaling components, transcription factors, miRs and their predicted targets in this process. Due to the complexity of these regulatory networks, large scale studies and comprehensive analyses are therefore needed to validate the role of these miRs in HIV infection, and determine the effect of their selective targeting in disease phenotype and outcome. Taken together experimental and bioinformatics analyses support the hypothesis that the STAT3-regulated miRs validated in our study may have a role in
the DC response to HIV. In this scenario, the determination of STAT3-dependent miR deregulation, their hypothetical targets and interaction network may provide a broader view of the host-virus interactions.

Methods
Ethics statements
Healthy donor buffy coats were obtained from Centro Trasfusionale University of Rome‘Sapienza’. Buffy coats were not obtained specifically for this study. Informed consent has not been asked because data were analyzed anonymously. Data from healthy donors have been treated by Centro Trasfusionale according to the Italian law on personal data management “Codice in materia di protezione dei dati personali” (Testo unico D.L. June 30, 2003 n. 196).

Reagents
All culture reagents were purchased from Biowhittaker as endotoxin-free lots. Ultra pure LPS from E. Coli (serotype EH100, Ra TL1grade) was purchased from Alexis Biochemicals (Nottingham, UK). Recombinant gp120 from CN54 HIV-1 strain was obtained from the national AIDS Research and Reference Reagent Program (Bethesda, MD). Recombinant CCL4 was purchased from R&D Systems. To test the effect of Stattic (Sigma, St Louis, MO), cells were treated prior to and during gp120 exposure with the inhibitor. Stattic did not exhibit any toxicity at the used concentration, as assessed by MTT assay (data not shown).

Cell separation and culture
Monocytes were isolated from PBMCs obtained from healthy donor buffy coats by immunomagnetic selection using CD14 microbeads (MACS monocyte isolation kit from MiltenyiBiotec, Auburn, CA), according to the manufacturer’s instructions. This procedure yields a pure (≥98 %) population of monocytes, as assessed by FACS analysis of lineage specific surface markers (CD1a, CD14, CD3, CD19, CD56). To obtain immature MDDCs, monocytes were cultured at 1 x 10^6 cells/ml in RPMI 1640 medium (Life Technologies, Gaithersburg, MD) containing 10 % FBS in the presence of GM-CSF (50 ng/ml) and IL-4 (500 U/ml). Cytokines were added to the cultures every 3 days. Both cytokines are kindly provided by Schering-Plough (Dardilly, France). On day 6, MDDCs were stimulated with LPS (10 ng/ml), gp120 (5 μg/ml), or CCL4 (100nM).

Prediction of transcription factor binding sites
To predict the putative STAT3 binding sites on precursor region upstream of the miRNA sequence, we considered the list of miRNAs predicted to have putative STAT3 binding sites which has been recently reported [16, 17]. Since for most of these miRNAs the putative binding region spanned several kilobases from the transcription start site, the calculated binding score ranged from 100 to 1000 and most of them have a quite low STAT3 binding score (<500), we decided to refine the analysis by considering only those miRNAs with a higher STAT3 binding score (>500) and by limiting the prediction to a region of 3000 bases upstream the miRNA sequence. For these miRNAs, the upstream sequences were extracted by the University of California Santa Cruz genome browser (UCSC) (https://genome.ucsc.edu/). These sequences were then used to identify the STAT3 binding motif using the LASAGNA-search software (http://biogrid-head.engr.uconn.edu/lasagna_search/) as previously described [61].

miRNA targets and STAT3 signaling pathway
Validated interactions among miRNAs and target genes belonging to STAT3 signaling pathway (Biocarta) were obtained by the curated database miRWalk (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) as previously described [62].

Gene ontology and pathways analysis
To determine the biological processes and signaling pathways in which the predicted targets of the deregulated miRs were involved, we performed Gene Ontology, KEGG pathway enrichment analysis and annotation by means of DAVID bioinformatics tool [29].

Expression of miRNAs
The expression of miRNAs were assessed by quantitative PCR (qPCR). Total RNA was extracted with the Total RNA Purification Plus Kit (Norgen Biotek, Canada) and converted into cDNA by using specific stem-loop primers [63]. The endogenous control let-7a was chosen as the endogenous miR since it displayed more constant expression values among all treatments with respect to U6 (data not shown). Relative quantification was performed by using the comparative Ct method [64]. qPCR was performed on an ABI-Prism 7900 HT (LifeTechnologies, Foster City, CA) using the SensiMix dT master mix (Bioline, London, UK), according to the manufacturer’s instructions.

Immunoblotting
MDDCs were stimulated with gp120 (5 μg/ml) for 18 h. Cell were lysed in RIPA buffer (150 mM NaCl, 50 mM Tris-Cl (pH 7.5), 1 % Nonidet P-40, 0.5 % sodium deoxycholate, and 0.1 % SDS) containing a cocktail of protease and phosphatase inhibitors and protein extracts were resolved by 8-12 % SDS-PAGE, transferred to a nitrocellulose membrane, and subjected to immunoblot analysis with antibodies specific for STAT-1, STAT ~3, SOCS1, NF-kB.
p50, IκBα, IKKβ, p38, ERK1/2, JNK, Akt and PIAS3 (Cell Signaling Technology; catalog numbers: 9172, 9139, 3950, 3035, 9242, 2684, 9212, 9102, 9252, 9272, 9042), and SOCS3, JAK2, STAT-2, NF-κB p65, Bcl2, BCLXL and PKR (Santa Cruz; catalog numbers: sc51699, sc476, sc81334, sc509, sc634, sc634, sc707), and actin (BD Transduction Laboratories; catalog numbers: 612656). Levels proteins were quantified using ImageJ software (software developed by Wayne Rasband, National Institutes of Health, Bethesda, MD).

Statistical analysis
Statistical comparison between various groups was performed by Student’s t-test or one way analysis of variance (ANOVA) with either least significant difference (LSD) or Bonferroni post hoc tests as appropriate, using the SPSS software (12.0.2). Comparisons were made between means from several experiments. Differences were considered significant when p values were < 0.05. Statistical significance is indicated with * for p < 0.05.

Deposition of data
Not applicable

Availability of supporting data
Other information is provided as supplementary files

Acknowledgements
This work was supported by a grant from the Italian Ministry of Health, Bando Nazionale AIDS 2009–2010, 3H/31 to SG. Bambino Gesù Children’s Hospital is also acknowledged for financial support to AM (RC-201302G003019). We are indebted to AIDS Reagents and Reference Program, Division of AIDS, NIAID, for providing the HIV-1 C564 gp120. We thank Fabiola Diamanti and Daniela Diamanti for excellent technical assistance.

Author details
1Bambino Gesù Children’s Hospital-IRCCS, Viale di San Paolo 15, 00146 Rome, Italy. *Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.

Received: 28 January 2015 Accepted: 29 May 2015
Published online: 27 June 2015

References
1. Guo YE, Steitz JA. Virus meets host microRNA: the destroyer, the booster, the hijacker. Mol Cell Biol. 2014;34:7180–7.
2. Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM, Zhang GZ. Biological functions of microRNAs: a review. J Physiol Biochem. 2011;67:129–39.
3. Tsang J, Zhu J, van Oudenaarden A. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol Cell. 2007;26:753–67.
4. Jolling CL, Yi M, Lancaster AM, Lemon SM, Samow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005;309:1577–81.
5. Locicero CH, Dunoyer P, Arar K, Lehmann-Che J, Evoyem S, Himber C, et al. A cellular microRNA mediates antiviral defense in human cells. Science. 2005;308:557–60.
6. Triboulet R, Benkirane M. Interplay between HIV-1 replication and the microRNA-silencing pathway. Med Sci. 2007;23:5590–2.
7. Yeung ML, Binnasaei Y, Myers TG, Jiang G, Benkirane M, Jeang KT. Changes in microRNA expression profiles in HIV-1-transfected human cells. Retrovirology. 2005;2:81–8.
8. Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H, et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4 T lymphocytic T lymphocytes. Nat Med. 2007;13:1241–7.
9. Swaminathan G, Navas-Martín S, Martín-García J. MicroRNAs and HIV-1 infection: antiviral activities and beyond. J Mol Biol. 2014;436:1718–27.
10. Witwer KW, Watson AK, Blankson JN, Clements JE. Relationships of PBMC microRNA expression, plasma viral load, and CD4 T-cell count in HIV-infected elite suppressors and viremic patients. Retrovirology. 2012;9:20–20.
11. Merad M, Sathe P, Heft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563–604.
12. Manches O, Frleta D, Bhardwaj N. Dendritic cells in progression and pathology of HIV infection. Trends Immunol. 2014;35:114–22.
13. Chougnet C, Gessani S. Role of gp120 in dendritic cell dysfunction in HIV infection. J Leukoc Biol. 2006;80:994–1000.
14. Del Corno M, Donninelli G, Varano B, Da Sacco L, Masotti A, Gessani S. HIV-1 gp120 activates the STAT3/interleukin-6 axis in primary human monocye-derived dendritic cells. J Virol. 2014;88:11045–55.
15. Cao Q, Li YY, He WF, Zhang ZZ, Zhou Q, Liu X, et al. Interplay between microRNAs and the STAT3 signaling pathway in human cancers. Physiol Genomics. 2013;45:1206–14.
16. Rozovski U, Calin GA, Setooyama T, D’Abundo L, Harris DM, Li P, et al. Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer. 2013;12:50.
17. Pennisi E. Genomics. ENCODE project writes eulogy for junk DNA. Science. 2012;337:1159–61.
18. Del Corno M, Donninelli G, Varano B, Da Sacco L, Masotti A, Gessani S. HIV-1 gp120 activates the STAT3/interleukin-6 axis in primary human monocye-derived dendritic cells. J Virol. 2014;88:11045–55.
19. Liu L, Li H, Li J, Zheng H, Zhang HC, Chen J, et al. miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. Biochem Biophys Res Commun. 2011;416:31–8.
21. Matsuhyama H, Suzuki HI, Nishimoto H, Noguchi M, Yao T, Komatsu N, et al. miR-135b mediates NFPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood. 2011;118:6881–92.

22. Schust J, Spert B, Hollis A, Mayer TU, Berg T. Static: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006;13:1235–42.

23. Del Corso M, Michiardi A, Masotti A, Da Sacco L, Bottazzo GF, Belardelli F, et al. CC chemokine ligand 2 down-modulation by selected Toll-like receptor agonist combinations contributes to T helper 1 polarization in human dendritic cells. Blood. 2009;114:796–806.

24. Ceppi M, Pereira PM, Dunand-Saithier I, Barrias E, Reith W, Santos MA, et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci U S A. 2009;106:2735–40.

25. Jin P, Han TH, Ren J, Saunders S, Wang E, Marincola FM, et al. Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med. 2010;8:4–19.

26. Busch M, Zernecke A. microRNAs in the regulation of dendritic cell functions in inflammation and atherosclerosis. J Mol Med (Berl). 2012;90:807–85.

27. Turner ML, Schnorrer FM, Brockier T. MicroRNAs regulate dendritic cell differentiation and function. J Immunol. 2011;187:3911–7.

28. Masotti A, Allisi A. Integrated bioinformatics analysis of microRNA expression profiles for an in-depth understanding of pathogenic mechanisms in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2012;27:1878–8.

29. da Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucl Acid Res. 2009;37:1–13.

30. Anand AR, Prasad A, Bradley RR, Deol YS, Nagaraja T, Ren X, et al. HIV-1 gp120-induced migration of dendritic cells is regulated by a novel kinase cascade involving Pyk2, p38 MAP kinase, and LSP1. Blood. 2009;114:5388–600.

31. Shan M, Klase PJ, Banerjee K, Dey AK, Iyer SP, Dinosio R, et al. HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog. 2007;3, e169.

32. Klase Z, Houzet L, Liang KT. MicroRNAs and HIV-1: complex interactions. J Biol Chem. 2012;287:40884–90.

33. Bivalk-Mehla S, Vakharia J, Mehta R, Abreha M, Kanwar JR, Toko A, et al. Viral RNA silencing suppressors (RNS): novel strategy of viruses to ablate the host RNA interference (RNAi) defense system. Virus Res. 2011;155:1–9.

34. Triboulet A, Mari L, Lin YL, Chable-Bessa C, Benneayer Y, Lebigrand K, et al. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science. 2007;315:1579–82.

35. Patel P, Ansari M, Bapar S, Thakur M, Gangakhedkar R, Jameel S. The microRNA miR-29a is associated with human immunodeficiency virus latency. Retrovirology. 2014;11:108–12.

36. Detsika MG, Psarris A, Paraskevis D. MicroRNAs and HIV latency: a complex and promising relationship. AIDS Rev. 2012;14:303–8.

37. Fantuzzi L, Canini I, Belardelli F, Gessani S. HIV-1 gp120 stimulates the production of beta-chemokines in human peripheral blood monocytes through a CD4-independent mechanism. J Immunol. 2001;166:3359–65.

38. Fantuzzi L, Purificato C, Donato K, Belardelli F, Gesani S. Human immunodeficiency virus type 1 gp120 induces abnormal maturation and functional alterations of dendritic cells: a novel mechanism for AIDS pathogenesis. J Virol. 2004;78:9763–72.

39. Martinez-Nunez RT, Louafi F, Friedmann PS, Sanchez-Elsner T. MicroRNA-155 modulates the pathway binding ability of dendritic cells (DCs) by down-regulation of DC-specific intercellular adhesion molecule-3 grabbing non-integrin (DC-SIGN). J Biol Chem. 2009;284:16334–42.

40. Narju P, Plakka-Kanthikkeel S, Raymond A, Aguado M, Vindant-Arias A, Saxena SK, et al. Cocaine enhances HIV-1 infectivity in monocyte derived dendritic cells by suppressing microRNA-155. PLoS One. 2013;8:e83682.

41. Lu C, Huang X, Zhang X, Roenck C, Cao Q, Nakayama KI, et al. miR-221 and miR-222 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KIP1, and SOCS-1. Blood. 2011;117:293–303.

42. Sun G, Li H, Wu X, Covamubias M, Scherer L, Meinking K, et al. Interplay between HIV-1 infection and host microRNAs. Nucl Acid Res. 2012;40:2181–96.

43. Tao T, Wang Y, Luo H, Yao L, Wang L, Wang J, et al. Involvement of FOS-mediated miR-181b/miR-21 signalling in the progression of malignant gliomas. Eur J Cancer. 2013;49:3565–73.

44. Ma X, Becker Buscaglia LE, Barker JR, Li Y. MicroRNAs in NF-kappaB signaling. J Mol Cell Biol. 2011;3:159–66.

45. Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, et al. MicroRNA-181B regulates NF-kappaB-mediated vascular inflammation. J Clin Invest. 2012;122:1973–90.

46. O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A. 2007;104:16049–54.

47. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O’Leary JJ, Ruan Q, et al. Negative regulation of TRLA via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol. 2011;12:1471–7.

48. Pirovano M, Manetti M, Cimi G, Paradisi M, Vuri C, Sentinelli E, et al. Novel pro-inflammatory mechanism of action of resistin in human endothelial cells: up-regulation of SOCS3 expression through STAT3 activation. Biochim Biophys Acta. 2011;1814:621–25.

49. Regis G, Pensa S, Boselli D, Novelli F, Poll V, Ups and downs: the Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120-stimulated primary human macrophages. Proc Natl Acad Sci U S A. 2009;106:13355–63.

50. Xu Y, Wang X, Li A, Zhang X, Hu J, Jiang J, et al. The miRNA miR-135b mediates the pathogen binding ability of dendritic cells to HIV-1. Retrovirology. 2011;8:292.

51. Oruc M, Kose Y, Dilek B, Kose F, Cakir A, Ergunes S, et al. MicroRNA expression and host response in HIV-1 infection. J Biol Chem. 2011;286:1037–11.

52. Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A. 2007;104:16049–54.

53. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O’Leary JJ, Ruan Q, et al. Negative regulation of TRLA via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol. 2011;12:1471–7.

54. Pirovano M, Manetti M, Cimi G, Paraditi M, Vuri C, Sentinelli E, et al. Novel pro-inflammatory mechanism of action of resistin in human endothelial cells: up-regulation of SOCS3 expression through STAT3 activation. Biochim Biophys Acta. 2011;1814:621–25.

55. Lee C, Huang CH. LASAGNA-Search: an integrated web tool for transcription factor binding site search and visualization. BioTechniques. 2013;54:141–5.